CBD Reduced Spinal-Cord-Injury Pain by a Modest Average Amount
High-dose CBD reduced reported neuropathic pain compared with placebo in a spinal-cord-injury trial, but the average difference was modest. Statistical significance did not imply a large benefit for every participant.
A blinded crossover treatment trial
Forty participants were randomized, and 38 contributed to the primary analysis. Oral CBD was titrated up to 800 mg per day during a six-week treatment period; participants also completed a placebo period separated by a four-week washout.
The primary outcome was self-reported pain intensity on a zero-to-ten scale. Participants had chronic spinal-cord-injury-associated neuropathic pain, so the findings should not be generalized to every type of pain or every CBD product.
Both the comparison and magnitude matter
During active treatment, mean pain intensity was approximately 0.54 points lower with CBD than placebo, with a confidence interval from 0.21 to 0.88 points lower. The inactive-phase treatment comparison was not significant.
The investigators described an average reduction consistent with a relatively small clinical change rather than the larger reduction often used to define moderate improvement. Some participants improved more than the average, but a responder subgroup does not guarantee a similar response in a new patient.
Benefit must be considered alongside tolerability
Adverse events were reported by 68.4% of participants during CBD and 52.6% during placebo; nearly all were minor. Participants also used other medications, which could not ethically be discontinued and might influence effects or interactions.
This was human randomized evidence, stronger for this question than animal pain models alone. Nevertheless, small sample size, concomitant treatment and the selected pain condition limit generalization. The appropriate conclusion is a modest average benefit under a high-dose protocol, with individual response and safety still requiring clinical assessment.
Related: How study design affects interpretation of CBD outcomes.
Primary research
High-dose cannabidiol for chronic neuropathic pain associated with spinal cord injury: a randomised clinical trial. eClinicalMedicine (2026).
